<DOC>
	<DOCNO>NCT00222807</DOCNO>
	<brief_summary>This preliminary study aim investigate mechanism high rate type 2 diabetes mellitus patient schizophrenia . As part study , collect neuroendocrine-immune data patient first episode , treatment naive psychosis , patient newly diagnose schizophrenia normal healthy control . Regardless treatment status , collect neuroendocrine-immune data participant 2 month .</brief_summary>
	<brief_title>Schizophrenia , Antipsychotic Treatment Risk Diabetes Mellitus</brief_title>
	<detailed_description>This preliminary study aim investigate mechanism high rate type 2 diabetes mellitus patient schizophrenia . As part study , collect neuroendocrine-immune data patient first episode , treatment naive psychosis , patient newly diagnose schizophrenia normal healthy control . Regardless treatment status , collect neuroendocrine-immune participant ( patient control ) 2 month . Thus , study control treatment . Patients take treatment consultation physician . Some even decide take medication . At 2nd visit , ask medication take .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Schizophrenia , Paranoid</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Psychotic disorder per DSMIV criterion American Psychiatric Association Diabetes , type 1 2 Prominent substance abuse ( i.e . psychotic symptom attributable entirely substance use ) Age 50 age 14</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>schizophrenia , psychosis , type 2 diabetes mellitus</keyword>
</DOC>